Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies

Bristol Myers Squibb (BMY.N) said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics.